Infection and Drug Resistance (Apr 2022)

Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections and Bloodstream Infections Caused by Staphylococcus aureus: A Comprehensive Review of the Evidence

  • Giacobbe DR,
  • Dettori S,
  • Corcione S,
  • Vena A,
  • Sepulcri C,
  • Maraolo AE,
  • De Rosa FG,
  • Bassetti M

Journal volume & issue
Vol. Volume 15
pp. 2137 – 2157

Abstract

Read online

Daniele Roberto Giacobbe,1,2 Silvia Dettori,1,2 Silvia Corcione,3 Antonio Vena,1,2 Chiara Sepulcri,1,2 Alberto Enrico Maraolo,4 Francesco Giuseppe De Rosa,3 Matteo Bassetti1,2 1Clinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, Genoa, Italy; 2Department of Health Sciences, University of Genoa, Genoa, Italy; 3Department of Medical Sciences, Division of Infectious Diseases, Azienda Ospedaliera Universitaria (A.O.U.) Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy; 4First Division of Infectious Diseases, Cotugno Hospital, AORN Dei Colli, Naples, ItalyCorrespondence: Daniele Roberto Giacobbe, Clinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, L.go R. Benzi 10, Genoa, 16132, Italy, Tel +390105554658, Email [email protected]: Staphylococcus aureus remains an important human pathogen of concern, with mortality rates surpassing 30% in the case of severe systemic infections. Distinguishing methicillin-susceptible S. aureus from methicillin-resistant S. aureus (MRSA) is fundamental for therapeutic choices. A crucial emerging concept in the treatment of acute bacterial skin and skin structure infections is the availability of various approved agents with anti-MRSA activity, which allow a personalized approach based on the characteristics of any given patient while at the same time remaining in line with high certainty efficacy evidence from large randomized controlled trials. Regarding the treatment of S. aureus bloodstream infections (BSI), interesting aspects that may become relevant in the near future are the presence of both old and novel agents in phase-2 or phase-3 of clinical development for this indication, and the pressing need for high certainty evidence to guide the possible use of combination therapy in specific categories or phenotypes of patients with complicated MRSA BSI.Keywords: Staphylococcus aureus, MSSA, MRSA, ABSSSI, BSI, bacteremia

Keywords